Furthermore, current standardized care for HBV, which has been expanded to include nucleos(t)ide analogues and pegylated interferon [13], has achieved better outcomes than IFN therapies, such as lower HCC incidence and overall mortality rates [14]–[16]. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.